- Trial Phase
- Phase 3
- Time to Market
- If Phase 3 data is positive (expected 2H 2026), regulatory filing could follow in 2027, with potential FDA approval in 2028 at the earliest.
- Why 7/10
- The next hard catalyst is the Phase 3 Himalayas-1 topline data readout for rinzimetostat in mCRPC, expected in 2H 2026 (within ~4 months). Rinzimetostat is ORIC's lead pipeline asset, and this pivotal readout is a major value driver for the company, which also has other programs (enozertinib).
Watch for rinzimetostat Phase 3 data readout expected in 2H 2026 (Himalayas-1 trial in mCRPC). Positive data would be a major catalyst for ORIC stock given rinzimetostat is the company's lead pipeline asset. The Bayer darolutamide collaboration strengthens the trial design without cost to ORIC.
Price Chart
Executive Summary
Rinzimetostat (ORIC-944) is ORIC Pharmaceuticals' lead drug candidate — an oral dual EZH1/EZH2 inhibitor in a global Phase 3 registrational trial (Himalayas-1) for metastatic castration-resistant prostate cancer (mCRPC). The company initiated the trial in mid-2026 with a clinical collaboration with Bayer for darolutamide supply. ORIC has a strong cash position (~$387.6M) funding operations into 2H 2028, and analysts are overwhelmingly bullish (10 Buy, 2 Hold, 0 Sell) with a mean price target of $20.67 (~56.5% upside). Key data catalysts are expected in 2H 2026, making this a high-impact near-term binary event for the stock.
How It Works
Rinzimetostat is a dual EZH1/EZH2 inhibitor — an oral pill that blocks two related epigenetic 'writer' enzymes (EZH1 and EZH2) that cancer cells use to silence tumor-suppressor genes. By inhibiting these enzymes, rinzimetostat aims to reactivate genes that normally suppress tumor growth, potentially slowing or stopping cancer progression. It is being studied in metastatic castration-resistant prostate cancer (mCRPC) in combination with darolutamide (an androgen receptor inhibitor supplied by Bayer).
Trial Status
The Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC was initiated in mid-2026. The recommended Phase 3 dose (RP3D) of 400 mg once daily was selected based on positive earlier-phase clinical data. The trial is being conducted in collaboration with Bayer, which supplies darolutamide at no cost. Key data readouts are expected in 2H 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 Himalayas-1 topline data readout for rinzimetostat in mCRPC (expected 2H 2026)
- Enozertinib 1L EGFR atypical monotherapy data at ESMO (October 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ORIC Pharmaceuticals PRESS-RELEASE ORIC ·Originating report